Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -2-
July 23, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 23, 2001
- BUSINESS NEWS IN BRIEF -1-
July 23, 2001
- Compact, Inexpensive Accelerators Necessary: Monkasho Survey
July 23, 2001
- Only 16% of Citizens Use Life-style Improving Drugs: Survey
July 23, 2001
- Kyowa Hakko to Start Marketing Cholesterol-lowering Super Soy in the US, Europe
July 23, 2001
- High-concentration Morphine HCl Preparations to Be Launched by 5 Companies
July 23, 2001
- ARB Inhibit Vascular Plaque Formation: Takeda Seminar
July 16, 2001
- REGULATORY NEWS IN BRIEF
July 16, 2001
- Polycarbophil Ca Useful against IBS: Fujisawa, Hokuriku Seminar
July 16, 2001
- New Working Group on Drugs, Medical Devices to Be Established: US-Japan Partnership
July 16, 2001
- Aspirin to Be Useful in Prevention of Economy Class Syndrome: Bayer Seminar
July 16, 2001
- DIAGNOSTIC NEWS IN BRIEF
July 16, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 16, 2001
- WORLD NEWS IN BRIEF -1-
July 16, 2001
- Therapeutic GLs Using EBM under Preparation in 4 Fields
July 16, 2001
- WORLD NEWS IN BRIEF -2-
July 16, 2001
- Control of Total Medical Costs Has No Durable Effect: Seminar
July 16, 2001
- Japanese Global Strategy Update (4)
July 16, 2001
- Kyowa Hakko to Focus on Cancer, Allergies: President Hirata
July 16, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…